AstroNova, Inc.

Q3 2022 Earnings Conference Call

12/8/2021

spk00: Good day and welcome to Astronova's third quarter fiscal 2022 financial results conference call. Today's conference is being recorded. I would now like to turn the conference over to Scott Solomon of the company's investor relations firm, Sharon Merrill Associates. Please go ahead, sir.
spk02: Thank you, John. Good morning, everyone, and thanks for joining us. Hosting this morning's call are Greg Woods, Astronova's president and CEO, and David Smith, the company's chief financial officer. Greg will discuss the company's operating results. David will take you through the financials at a high level. Greg will make concluding comments. And then management will be happy to take your questions. By now, you should have received a copy of the earnings release that was issued today. If you do not have a copy, please go to the investors' page of the Astronova website, www.astronovainc.com. Please note that statements made during today's call that are not statements of historical fact are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1934. These forward-looking statements are based on a number of assumptions that could involve risks and uncertainties. Accordingly, actual results could differ materially except as required by law. Any forward-looking statements speak only as of today, December 8, 2021. The company undertakes no obligation to update these forward-looking statements. For further information regarding the forward-looking statements and the factors that may cause differences, please see the risk factors in Astronova's annual report on Form 10-K and other filings the company makes with the Securities and Exchange Commission. On today's call, management will be referring to non-GAAP financial measures, including non-GAAP net income and non-GAAP net income per diluted share. Astronova believes that the inclusion of these measures help investors gain a meaningful understanding of the changes and the company's core operating results, and also can help investors who wish to make comparisons between Astronova and other companies on both a GAAP and a non-GAAP basis. A reconciliation of these non-GAAP measures to their most directly comparable GAAP measures is available in today's earnings release. And with that, I'll turn the call over to Greg.
spk01: Thank you, Scott. Good morning, everyone, and thank you for joining us. As you mentioned in this morning's press release, we continue to see global demand growth for our products and services. And overall, our teams performed well in the third quarter, despite a number of supply chain constraints that affected our results. Total revenue in the quarter increased 3% year-over-year to $28.9 million. The continued rebound of the commercial aviation market helped us deliver sequential and year-over-year growth in our test and measurement segments. Revenue in the T&M segment increased 35% in the third quarter to $6.9 million, making it the best quarter since last year's first quarter. This more than offset a slight decline in the product identification revenue, which was down 4% to $21.9 million. Our strong third quarter bookings came in at a $32.3 million rate, up 16% year-over-year and up 6% sequentially from Q2. A big challenge for us during the quarter was the difficulty in obtaining certain electronic components, which prevented us from making several late-quarter shipments. However, thanks to our materials teams, we have since received the majority of the delayed components and expect to ship those held-up orders in the fourth quarter. This includes revenue from the new multi-year government program I referenced on our last call, a program that involves supplying advanced data acquisition equipment for aerospace and defense applications. Looking at revenue by type, supplies and hardware revenue remain roughly flat with the third quarter of fiscal 2021, while service and other revenue was up 35% from the same period last year, the bulk of which was in T&M. From a geographic perspective, U.S. revenue accounted for approximately 60% of our total sales in Q3. We continue to strengthen our product identification teams both domestically and internationally. For example, We recently hired a head of production responsible for our growing media business in Europe, Middle East, and Africa, and new initiatives there are beginning to generate positive results already. On our Q2 call, I noted that we had begun to return to in-person meetings and trade shows. During the third quarter, we exhibited our latest printing and labeling products at a number of in-person events. These included two major trade shows, the Pack Expo and Healthcare Packaging Shows in Las Vegas, and FACFAC, the European Trade Fair for Packaging in Nuremberg, Germany. Attendees had the opportunity to demo our industry-leading technologies, including the QL120D, the QL850, the QL300, and the T2C, as well as our new T3-OPX direct-to-package printing system. We also engaged in great discussions with our current and prospective customers about how our product identification solutions play into global trends related to digital print for packaging and environmental sustainability. Since the end of Q3, we have also participated in some smaller regional shows in North America, Europe, and Asia. As a matter of fact, we have one going on right now in New York City. While we are being judicious, about adding trade shows related to expenses, early indications are that the quality of leads generated from these shows continues to be very high because the attendees are there for solid business reasons. Going forward, we plan to pursue a hybrid marketing approach that combines both select high-value in-person events as well as continued growth in our digital marketing platforms. On the digital front, We will continue to expand our e-books, case studies, support videos, and other cost-effective digital tools that have proven successful in enhancing our sales and customer support activities. Looking ahead, we expect revenue to increase on a sequential and year-over-year basis in the fourth quarter of fiscal 2022. Now let me turn the call over to David for the financial review.
spk04: Thanks, Greg, and good morning, everybody. Rather than repeat the number information and the press release or Greg's remarks, I'm going to briefly highlight a few key items in the P&L and balance sheet. Our press release tables disclose in all the required detail the gap and non-gap reconciliations. To summarize, the non-GAAP figures exclude the benefits we received from the CARES Act, plus they include the write-off in the third quarter of our old legacy domestic MRP system. In the interest of efficiency, I'm going to comment primarily on the non-GAAP results. But please also refer to the reconciliation tables we've provided, which have the actual gap results. Operating expenses in the third quarter were up about 8% from the same period in fiscal 21. Last year, we were still in a COVID-induced cost-constrained uncertainty posture, and we're now responding to visible growth opportunities. The increase is concentrated in higher R&D expenses associated with new product development in our product identification segment, and we will continue targeted investments in organic growth. Year to date through the third quarter, non-GAAP operating expenses are running about 70 basis points higher as a percentage of sales than last year. and non-GAAP quarterly OPEX is about 4 percent higher year-over-year in this current quarter, in line with revenue growth and consistent with our current outlook. Looking at operating segment operating margins this quarter, product identification posted an operating margin of 1.8 million or 8.3 percent of revenue compared with 3.5 million or 15.4 percent in the third quarter of fiscal 21. The decrease is primarily attributable to lower revenue and mixed effects. Test and measurement segment operating margin in Q3 this year was a million dollars or about 16.8 percent, representing a positive swing of about a million and a half from the third quarter of last year. which saw an operating loss of almost $700,000 or 14.7%. Year-to-date through Q3, GAAP segment operating profit for product identification was $8.9 million or 13.8%, excluding the CARES Act benefits. And on a non-GAAP basis, the segment operating margin was $7.5 million or 11%. Year-to-date for test and measurement, GAAP segment operating profit was 2.9 million or 15.1%. And on a non-GAAP basis, excluding the CARES Act benefits, the segment operating margin was 2.1 million or 10.9%. Q3 marked a major operational accomplishment for the company. with the initial go-live of our new enterprise resource planning system. The rollout of a new ERP system requires significant resources for a company of any size, even more so given the economic headwinds and the business disruptions associated with the COVID environment. This implementation has been a long process, and the large team that has accomplished this has put the company in a position to grow and prosper in the future. As noted in the press release this morning, on a GAAP basis reported a net loss of $425,000, or six cents a share, which includes about $700,000 in other expense associated with the write-down of our decades-old legacy ERP system. On a non-GAAP basis, excluding that expense, that income was $76,000 or one cent per share. Coming to the balance sheet, cash and equivalents at the end of the quarter stood at $8.7 million, down from about $11.4 million at the end of the year. Total debt at the end of the quarter was $9.4 million, down from approximately $17 million at year end. We're in a very strong position relative to our bank covenant structure, and we have ample capacity under the bank facility to fund future growth. Tomorrow, we'll be presenting and hosting one-on-ones at the Sedoti December virtual microcap conference. If you'd like to schedule a meeting, please email us at ALOT at investorrelations.com. Now, let me turn the call back to Greg for a few closing comments.
spk01: Thanks, David. In summary, Our team executed well in the third quarter in spite of the global supply chain challenges. And while we remain mindful about the potential for continued economic uncertainty related to COVID-19 on our end markets, with our strong bookings and a solid backlog, we feel we are well positioned for sequential and year-over-year growth in the fourth quarter. Now, David and I would be happy to take your questions. Operator?
spk00: Thank you. Ladies and gentlemen, if you would like to ask a question, please signal by pressing star followed by 1. That is star 1 to queue for a question. We'll pause for a brief moment to allow everyone an opportunity to signal for questions. As a reminder, that is star 1 to queue for a question, star 1 We will take our first question from Dick Ryan of Colliers. Please go ahead. Your line is now open.
spk03: Thank you. Hey, Greg, how much was the revenue impact in Q3 from the supply chain issues? It looks like you're going to make that up in Q4, but what was the Q3 impact?
spk01: I don't think we disclosed that, but it was a significant number. Yeah, it was a fairly large shipment, I guess. So I'm going to leave it at that. But like I mentioned earlier, we have the stuff in hand, so I have no doubt that we'll ship that out this quarter along with our normal business for the quarter.
spk03: Okay. And I may have missed, but did you guys break out? I was looking at what the recurring revenue number was for the quarter, supplies, and then with services.
spk01: I know it's in our queue. Is that on the release there, David?
spk04: It wasn't in the release. I don't have the number right at the top of my head, but I'll pop back in before the call is over and give it to you.
spk03: Sure, no problem. Hey, Greg, when you look at the future growth, are you looking from the M&A standpoint as well, and can you kind of give us a little color as to how that environment looks at the current time?
spk01: Sure. Yeah, as you know, it's been part of our strategic plan from the beginning, when we first put that in place, you know, probably seven years ago. But we, and probably as you also know, we were kind of out of that arena for a little while during COVID and the related bank restrictions. But, you know, that all kind of freed up, you know, as you mentioned earlier this year, and we have been quite active in terms of screening potential deals. You know, obviously nothing to report, but, What I can report is the activity is up, and that is part of our strategy. And, you know, we're hopeful that, you know, you never know, you know, sometime in the next several quarters we can put something together. But that is a very active part of our strategy. And actually both segments, the test and measurement segment as well as the PI segment.
spk03: Okay. And just on the test and measurement side, was any of this new arrow – Aerospace and defense, when did that contribute in Q3, or was the results pretty much commercial transport?
spk01: That was mostly – it was almost all commercial. So that order that I referenced and some of the other business that typically happens in the fourth quarter will happen, plus this order that we couldn't get out the door will come out in the fourth quarter.
spk03: Okay, great. Thank you.
spk01: Sure, Dick.
spk00: And it appears there are no further questions. I would now like to hand the call for closing remarks to Mr. Woods.
spk01: Great. Well, thank you all for joining us here this morning. We look forward to keeping you up to date on the progress. And if you're able to, you can join us at the Sedoti Conference that David mentioned tomorrow. Otherwise, have a happy and healthy holiday. Goodbye for now.
spk00: Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-